Complement inhibition and FcRn saturation are among the mechanisms of action also seen in IVIG; therefore, it will be interesting to see how these single-target agents, once approved, will fit into the CIDP treatment landscape. Here, FCGRT is linked to chronic inflammatory demyelinating polyradiculoneuropathy.